On Slide 7, you can see our next chapter in Hematology is driven by two complementary pla…

“On Slide 7, you can see our next chapter in Hematology is driven by two complementary platforms targeted protein degradation and cell therapy. Starting with targeted protein degradation, we are building on our legacy with a new wave of innovative science across therapeutic areas, with multiple assets in development. Our researchers are leveraging three different modalities for targeted protein degraders CELMoDs, Ligand Directed Degraders and Degrader antibody conjugates. These three-pronged approach allows us to match the right modality to a mechanism of action to target what that have previously been considered undruggable targets. One of the most exciting qualities of these assets is that they are highly combinable with other approaches such as targeted therapies, immune modulators, CAR-T cell therapies, and also complex biologics.”